Early findings indicate that these mAbs in combination with PD-1 inhibitors achieve higher response rates compared to PD-1/PD-L1 inhibition alone, likely driven by synergistic mechanisms such as enhanced activation of NK cells and CD8+ tumor-infiltrating lymphocytes (TILs). This evidence concerns the gene CD8A and neoplasm.